Novel approaches to whole sporozoite vaccination against malaria

Vaccine

Volumn 33, Issue 52, 2015, Pages 7462-7468

  Bijker, Else M ^a   Borrmann, Steffen ^b,c   Kappe, Stefan H ^d,e   Mordmüller, Benjamin ^b,f   Sack, Brandon K ^d   Khan, Shahid M ^g  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^d SEATTLE BIOMEDICAL RESEARCH INSTITUTE   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f Alberts Schweitzer Hospital   (Gabon)

^g LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Chemoprophylaxis; Chloroquine; Genetic attenuation; Immunization; Liver stage; Malaria; Plasmodium; Pre erythrocytic stages; Sporozoite; Vaccine

Indexed keywords

LIVE VACCINE; MALARIA VACCINE; SPOROZOITE VACCINE; ANTIMALARIAL AGENT; CHLOROQUINE;

ARTICLE; CHEMOPROPHYLAXIS; DNA MODIFICATION; GENE DELETION; GENETICALLY ATTENUATED PARASITE; HOMOLOGOUS RECOMBINATION; HUMAN; LIVER DEVELOPMENT; MALARIA; MASS IMMUNIZATION; NONHUMAN; PLASMODIUM; PRIORITY JOURNAL; SPOROZOITE; TRANSGENIC ORGANISM; VACCINATION; ANIMAL; GENETICS; IMMUNOLOGY; MOUSE; PLASMODIUM FALCIPARUM; PRE-EXPOSURE PROPHYLAXIS; PRECLINICAL STUDY; PROCEDURES; RADIATION RESPONSE;

ANIMALS; ANTIMALARIALS; CHLOROQUINE; DRUG EVALUATION, PRECLINICAL; HUMANS; MALARIA; MALARIA VACCINES; MICE; PLASMODIUM; PLASMODIUM FALCIPARUM; PRE-EXPOSURE PROPHYLAXIS; SPOROZOITES; VACCINATION; VACCINES, ATTENUATED;

EID: 84951086001     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.09.095     Document Type: Article

References (90)

1. Langhorne J., Ndungu F.M., Sponaas A.M., Marsh K. Immunity to malaria: more questions than answers. Nat Immunol 2008, 9(7):725-732.
2. WHO World malaria report 2014.
3. The malERA Consultative Group on Vaccines A research agenda for malaria eradication: vaccines. PLoS Med 2011, 8(1):e1000398.
4. Hellriegel B. Immunoepidemiology-bridging the gap between immunology and epidemiology. Trends Parasitol 2001, 17(2):102-106.
5. Tran T.M., Li S., Doumbo S., Doumtabe D., Huang C.Y., Dia S., et al. An intensive longitudinal cohort study of Malian children and adults reveals no evidence of acquired immunity to Plasmodium falciparum infection. Clin Infect Dis 2013, 57(1):40-47. (an official publication of the Infectious Diseases Society of America).
6. Bijker E.M., Bastiaens G.J., Teirlinck A.C., van Gemert G.J., Graumans W., van de Vegte-Bolmer M., et al. Protection against malaria after immunization by chloroquine prophylaxis and sporozoites is mediated by preerythrocytic immunity. Proc Natl Acad Sci USA 2013, 110(19):7862-7867.
7. Good M.F., Doolan D.L. Malaria vaccine design: immunological considerations. Immunity 2010, 33(4):555-566.
8. Doolan D.L., Dobano C., Baird J.K. Acquired immunity to malaria. Clin Microbiol Rev 2009, 22(1):13-36.
9. Tarun A.S., Peng X., Dumpit R.F., Ogata Y., Silva-Rivera H., Camargo N., et al. A combined transcriptome and proteome survey of malaria parasite liver stages. Proc Natl Acad Sci USA 2008, 105(1):305-310.
10. Nahrendorf W., Spence P.J., Tumwine I., Levy P., Jarra W., Sauerwein R.W., et al. Blood-stage immunity to Plasmodium chabaudi malaria following chemoprophylaxis and sporozoite immunization. Elife 2015, 25:4. 10.7554/eLife.05165.
11. Butler N.S., Schmidt N.W., Vaughan A.M., Aly A.S., Kappe S.H., Harty J.T. Superior antimalarial immunity after vaccination with late liver stage-arresting genetically attenuated parasites. Cell Host Microbe 2011, 9(6):451-462.
12. Sack B.K., Keitany G.J., Vaughan A.M., Miller J.L., Wang R., Kappe S.H. Mechanisms of stage-transcending protection following immunization of mice with late liver stage-arresting genetically attenuated malaria parasites. PLoS Pathog 2015, 11(5):e1004855.
13. Doll K.L., Butler N.S., Harty J.T. CD8T cell independent immunity after single dose infection-treatment-vaccination (ITV) against Plasmodium yoelii. Vaccine 2014, 32(4):483-491.
14. Beaudoin R.L., Strome C.P., Mitchell F., Tubergen T.A. Plasmodium berghei: immunization of mice against the ANKA strain using the unaltered sporozoite as an antigen. Exp Parasitol 1977, 42(1):1-5.
15. Golenser J., Heeren J., Verhave J.P., Kaay H.J., Meuwissen J.H. Crossreactivity with sporozoites, exoerythrocytic forms and blood schizonts of Plasmodium berghei in indirect fluorescent antibody tests with sera of rats immunized with sporozoites or infected blood. Clin Exp Immunol 1977, 29(1):43-51.
16. Orjih A.U., Cochrane A.H., Nussenzweig R.S. Comparative studies on the immunogenicity of infective and attenuated sporozoites of Plasmodium berghei. Trans R Soc Trop Med Hyg 1982, 76(1):57-61.
17. Roestenberg M., McCall M., Hopman J., Wiersma J., Luty A.J., van Gemert G.J., et al. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 2009, 361(5):468-477.
18. Roestenberg M., Teirlinck A.C., McCall M.B., Teelen K., Makamdop K.N., Wiersma J., et al. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 2011, 377(9779):1770-1776.
19. Bijker E.M., Schats R., Obiero J.M., Behet M.C., van Gemert G.J., van de Vegte-Bolmer M., et al. Sporozoite immunization of human volunteers under mefloquine prophylaxis is safe, immunogenic and protective: a double-blind randomized controlled clinical trial. PLoS ONE 2014, 9(11):e112910.
20. Bijker E.M., Teirlinck A.C., Schats R., van Gemert G.J., van de Vegte-Bolmer M., van Lieshout L., et al. Cytotoxic markers associate with protection against malaria in human volunteers immunized with Plasmodium falciparum sporozoites. J Infect Dis 2014, 210(10):1605-1615.
21. Belnoue E., Costa F.T., Frankenberg T., Vigario A.M., Voza T., Leroy N., et al. Protective T cell immunity against malaria liver stage after vaccination with live sporozoites under chloroquine treatment. J Immunol 2004, 172(4):2487-2495.
22. Culleton R.L., Inoue M., Reece S.E., Cheesman S., Carter R. Strain-specific immunity induced by immunization with pre-erythrocytic stages of Plasmodium chabaudi. Parasite Immunol 2011, 33(1):73-78.
23. Inoue M., Tang J., Miyakoda M., Kaneko O., Yui K., Culleton R. The species specificity of immunity generated by live whole organism immunisation with erythrocytic and pre-erythrocytic stages of rodent malaria parasites and implications for vaccine development. Int J Parasitol 2012, 42(9):859-870.
24. Peng X., Keitany G.J., Vignali M., Chen L., Gibson C., Choi K., et al. Artesunate versus chloroquine infection-treatment-vaccination defines stage-specific immune responses associated with prolonged sterile protection against both pre-erythrocytic and erythrocytic Plasmodium yoelii infection. J Immunol 2014, 193(3):1268-1277.
25. Hoffman S.L., Goh L.M., Luke T.C., Schneider I., Le T.P., Doolan D.L., et al. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 2002, 185(8):1155-1164.
26. Slater A.F. Chloroquine: mechanism of drug action and resistance in Plasmodium falciparum. Pharmacol Ther 1993, 57(2-3):203-235.
27. Mazier D., Renia L., Snounou G. A pre-emptive strike against malaria's stealthy hepatic forms. Nat Rev Drug Discov 2009, 8(11):854-864.
28. Dahl E.L., Rosenthal P.J. Multiple antibiotics exert delayed effects against the Plasmodium falciparum apicoplast. Antimicrob Agents Chemother 2007, 51(10):3485-3490.
29. Friesen J., Silvie O., Putrianti E.D., Hafalla J.C., Matuschewski K., Borrmann S. Natural immunization against malaria: causal prophylaxis with antibiotics. Sci Transl Med 2010, 2(40):40.
30. Friesen J., Borrmann S., Matuschewski K. Induction of antimalaria immunity by pyrimethamine prophylaxis during exposure to sporozoites is curtailed by parasite resistance. Antimicrob Agents Chemother 2011, 55(6):2760-2767.
31. Friesen J., Matuschewski K. Comparative efficacy of pre-erythrocytic whole organism vaccine strategies against the malaria parasite. Vaccine 2011, 29(40):7002-7008.
32. Pfeil J., Sepp K.J., Heiss K., Meister M., Mueller A.K., Borrmann S. Protection against malaria by immunization with non-attenuated sporozoites under single-dose piperaquine-tetraphosphate chemoprophylaxis. Vaccine 2014, 32(45):6005-6011.
33. Nganou-Makamdop K., Sauerwein R.W. Liver or blood-stage arrest during malaria sporozoite immunization: the later the better?. Trends Parasitol 2013, 29(6):304-310.
34. van Dijk M.R., Waters A.P., Janse C.J. Stable transfection of malaria parasite blood stages. Science 1995, 268(5215):1358-1362.
35. Menard R., Janse C. Gene targeting in malaria parasites. Methods 1997, 13(2):148-157.
36. Matuschewski K., Ross J., Brown S.M., Kaiser K., Nussenzweig V., Kappe S.H. Infectivity-associated changes in the transcriptional repertoire of the malaria parasite sporozoite stage. J Biol Chem 2002, 277(44):41948-41953.
37. Kaiser K., Matuschewski K., Camargo N., Ross J., Kappe S.H. Differential transcriptome profiling identifies Plasmodium genes encoding pre-erythrocytic stage-specific proteins. Mol Microbiol 2004, 51(5):1221-1232.
38. Vaughan A.M., Wang R., Kappe S.H. Genetically engineered, attenuated whole-cell vaccine approaches for malaria. Hum Vaccin 2010, 6(1):107-113.
39. Khan S.M., Janse C.J., Kappe S.H., Mikolajczak S.A. Genetic engineering of attenuated malaria parasites for vaccination. Curr Opin Biotechnol 2012, 23(6):908-916.
40. Spring M., Murphy J., Nielsen R., Dowler M., Bennett J.W., Zarling S., et al. First-in-human evaluation of genetically attenuated Plasmodium falciparum sporozoites administered by bite of Anopheles mosquitoes to adult volunteers. Vaccine 2013, 31(43):4975-4983.
41. Doll K.L., Harty J.T. Correlates of protective immunity following whole sporozoite vaccination against malaria. Immunol Res 2014, 59(1-3):166-176.
42. Nganou-Makamdop K., Ploemen I., Behet M., Van Gemert G.J., Hermsen C., Roestenberg M., et al. Reduced Plasmodium berghei sporozoite liver load associates with low protective efficacy after intradermal immunization. Parasite Immunol 2012, 34(12):562-569.
43. Kappe S.H., Gardner M.J., Brown S.M., Ross J., Matuschewski K., Ribeiro J.M., et al. Exploring the transcriptome of the malaria sporozoite stage. Proc Natl Acad Sci USA 2001, 98(17):9895-9900.
44. Mueller A.K., Camargo N., Kaiser K., Andorfer C., Frevert U., Matuschewski K., et al. Plasmodium liver stage developmental arrest by depletion of a protein at the parasite-host interface. Proc Natl Acad Sci USA 2005, 102(8):3022-3027.
45. Mueller A.K., Labaied M., Kappe S.H., Matuschewski K. Genetically modified Plasmodium parasites as a protective experimental malaria vaccine. Nature 2005, 433(7022):164-167.
46. van Dijk M.R., Douradinha B., Franke-Fayard B., Heussler V., van Dooren M.W., van Schaijk B., et al. Genetically attenuated P36 p-deficient malarial sporozoites induce protective immunity and apoptosis of infected liver cells. Proc Natl Acad Sci USA 2005, 102(34):12194-12199.
47. van Schaijk B.C., Janse C.J., van Gemert G.J., van Dijk M.R., Gego A., Franetich J.F., et al. Gene disruption of Plasmodium falciparum p52 results in attenuation of malaria liver stage development in cultured primary human hepatocytes. PLoS ONE 2008, 3(10):e3549.
48. Annoura T., Ploemen I.H., van Schaijk B.C., Sajid M., Vos M.W., van Gemert G.J., et al. Assessing the adequacy of attenuation of genetically modified malaria parasite vaccine candidates. Vaccine 2012, 30(16):2662-2670.
49. VanBuskirk K.M., O'Neill M.T., De La Vega P., Maier A.G., Krzych U., Williams J., et al. Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci USA 2009, 106(31):13004-13009.
50. van Schaijk B.C., Ploemen I.H., Annoura T., Vos M.W., Lander F., van Gemert G.-J., et al. A genetically attenuated malaria vaccine candidate based on P. falciparum b9/slarp gene-deficient sporozoites. Elife 2014, 19:3. 10.7554/eLife.03582.
51. Annoura T., van Schaijk B.C., Ploemen I.H., Sajid M., Lin J.W., Vos M.W., et al. Two Plasmodium 6-Cys family-related proteins have distinct and critical roles in liver-stage development. FASEB J 2014, 28(5):2158-2170.
52. Lasonder E., Janse C.J., van Gemert G.J., Mair G.R., Vermunt A.M., Douradinha B.G., et al. Proteomic profiling of Plasmodium sporozoite maturation identifies new proteins essential for parasite development and infectivity. PLoS Pathog 2008, 4(10):e1000195.
53. Aly A.S., Mikolajczak S.A., Rivera H.S., Camargo N., Jacobs-Lorena V., Labaied M., et al. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection. Mol Microbiol 2008, 69(1):152-163.
54. Silvie O., Goetz K., Matuschewski K. A sporozoite asparagine-rich protein controls initiation of Plasmodium liver stage development. PLoS Pathog 2008, 4(6):e1000086.
55. Aly A.S., Lindner S.E., MacKellar D.C., Peng X., Kappe S.H. SAP1 is a critical post-transcriptional regulator of infectivity in malaria parasite sporozoite stages. Mol Microbiol 2011, 79(4):929-939.
56. Mikolajczak S.A., Lakshmanan V., Fishbaugher M., Camargo N., Harupa A., Kaushansky A., et al. A next-generation genetically attenuated Plasmodium falciparum parasite created by triple gene deletion. Mol Ther 2014, 22(9):1707-1715. (the journal of the American Society of Gene Therapy).
57. van Schaijk B.C., Kumar T.R., Vos M.W., Richman A., van Gemert G.J., Li T., et al. Type II fatty acid biosynthesis is essential for Plasmodium falciparum sporozoite development in the midgut of Anopheles mosquitoes. Eukaryot Cell 2014, 13(5):550-559.
58. van Schaijk B.C., Vos M.W., Janse C.J., Sauerwein R.W., Khan S.M. Removal of heterologous sequences from Plasmodium falciparum mutants using FLPe-recombinase. PLoS ONE 2010, 5(11):e15121.
59. O'Neill M.T., Phuong T., Healer J., Richard D., Cowman A.F. Gene deletion from Plasmodium falciparum using FLP and Cre recombinases: implications for applied site-specific recombination. Int J Parasitol 2011, 41(1):117-123.
60. Yeh E., DeRisi J.L. Chemical rescue of malaria parasites lacking an apicoplast defines organelle function in blood-stage Plasmodium falciparum. PLoS Biol 2011, 9(8):e1001138.
61. Nagel A., Prado M., Heitmann A., Tartz S., Jacobs T., Deschermeier C., et al. A new approach to generate a safe double-attenuated Plasmodium liver stage vaccine. Int J Parasitol 2013, 43(6):503-514.
62. Purcell L.A., Yanow S.K., Lee M., Spithill T.W., Rodriguez A. Chemical attenuation of Plasmodium berghei sporozoites induces sterile immunity in mice. Infect Immun 2008, 76(3):1193-1199.
63. Purcell L.A., Wong K.A., Yanow S.K., Lee M., Spithill T.W., Rodriguez A. Chemically attenuated Plasmodium sporozoites induce specific immune responses, sterile immunity and cross-protection against heterologous challenge. Vaccine 2008, 26(38):4880-4884.
64. Schofield L., Villaquiran J., Ferreira A., Schellekens H., Nussenzweig R., Nussenzweig V. Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature 1987, 330(6149):664-666.
65. Weiss W.R., Sedegah M., Beaudoin R.L., Miller L.H., Good M.F. CD8+ T cells (cytotoxic/suppressors) are required for protection in mice immunized with malaria sporozoites. Proc Natl Acad Sci USA 1988, 85(2):573-576.
66. Trimnell A., Takagi A., Gupta M., Richie T.L., Kappe S.H., Wang R. Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes. J Immunol 2009, 183(9):5870-5878.
67. Cockburn I.A., Amino R., Kelemen R.K., Kuo S.C., Tse S.W., Radtke A., et al. In vivo imaging of CD8+ T cell-mediated elimination of malaria liver stages. Proc Natl Acad Sci USA 2013, 110(22):9090-9095.
68. Cockburn I.A., Tse S.W., Zavala F. CD8+ T cells eliminate liver stage Plasmodium parasites without detectable bystander effect. Infect Immun 2014, 82(4):1460-1464.
69. Epstein J.E., Tewari K., Lyke K.E., Sim B.K., Billingsley P.F., Laurens M.B., et al. Live attenuated malaria vaccine designed to protect through hepatic CD8(+) T cell immunity. Science 2011, 334(6055):475-480.
70. Tse S.W., Radtke A.J., Espinosa D.A., Cockburn I.A., Zavala F. The chemokine receptor CXCR6 is required for the maintenance of liver memory CD8(+) T cells specific for infectious pathogens. J Infect Dis 2014, 210(9):1508-1516.
71. Mueller A.K., Deckert M., Heiss K., Goetz K., Matuschewski K., Schluter D. Genetically attenuated Plasmodium berghei liver stages persist and elicit sterile protection primarily via CD8 T cells. Am J Pathol 2007, 171(1):107-115.
72. Jobe O., Lumsden J., Mueller A.K., Williams J., Silva-Rivera H., Kappe S.H., et al. Genetically attenuated Plasmodium berghei liver stages induce sterile protracted protection that is mediated by major histocompatibility complex Class I-dependent interferon-gamma-producing CD8+ T cells. J Infect Dis 2007, 196(4):599-607.
73. Tarun A.S., Dumpit R.F., Camargo N., Labaied M., Liu P., Takagi A., et al. Protracted sterile protection with Plasmodium yoelii pre-erythrocytic genetically attenuated parasite malaria vaccines is independent of significant liver-stage persistence and is mediated by CD8+ T cells. J Infect Dis 2007, 196(4):608-616.
74. Rodrigues M., Nussenzweig R.S., Zavala F. The relative contribution of antibodies, CD4+ and CD8+ T cells to sporozoite-induced protection against malaria. Immunology 1993, 80(1):1-5.
75. Chen D.H., Tigelaar R.E., Weinbaum F.I. Immunity to sporozoite-induced malaria infection in mice. I. The effect of immunization of T and B cell-deficient mice. J Immunol 1977, 118(4):1322-1327.
76. Egan J.E., Weber J.L., Ballou W.R., Hollingdale M.R., Majarian W.R., Gordon D.M., et al. Efficacy of murine malaria sporozoite vaccines: implications for human vaccine development. Science 1987, 236(4800):453-456.
77. Vanderberg J.P., Frevert U. Intravital microscopy demonstrating antibody-mediated immobilisation of Plasmodium berghei sporozoites injected into skin by mosquitoes. Int J Parasitol 2004, 34(9):991-996.
78. Sack B.K., Miller J.L., Vaughan A.M., Douglass A., Kaushansky A., Mikolajczak S.A., et al. A model for in vivo assessment of humoral protection against malaria sporozoite challenge by passive transfer of monoclonal antibodies and immune serum. Infect Immun 2014, 82(2):808-817.
79. Seder R.A., Chang L.J., Enama M.E., Zephir K.L., Sarwar U.N., Gordon I.J., et al. Protection against malaria by intravenous immunization with a nonreplicating sporozoite vaccine. Science 2013, 341(6152):1359-1365.
80. Felgner P.L., Roestenberg M., Liang L., Hung C., Jain A., Pablo J., et al. Pre-erythrocytic antibody profiles induced by controlled human malaria infections in healthy volunteers under chloroquine prophylaxis. Sci Rep 2013, 3:3549.
81. Behet M.C., Foquet L., van Gemert G.J., Bijker E.M., Meuleman P., Leroux-Roels G., et al. Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. Malar J 2014, 13:136.
82. Nahrendorf W., Scholzen A., Bijker E.M., Teirlinck A.C., Bastiaens G.J., Schats R., et al. Memory B-cell and antibody responses induced by Plasmodium falciparum sporozoite immunization. J Infect Dis 2014, 210(12):1981-1990.
83. Finney O.C., Keitany G.J., Smithers H., Kaushansky A., Kappe S., Wang R. Immunization with genetically attenuated P. falciparum parasites induces long-lived antibodies that efficiently block hepatocyte invasion by sporozoites. Vaccine 2014, 32(19):2135-2138.
84. Keitany G.J., Sack B., Smithers H., Chen L., Jang I.K., Sebastian L., et al. Immunization of mice with live-attenuated late liver stage-arresting P. yoelii parasites generates protective antibody responses to pre-erythrocytic stages of malaria. Infect Immun 2014, 32(19):2135-2138.
85. Roestenberg M., Bijker E.M., Sim B.K., Billingsley P.F., James E.R., Bastiaens G.J., et al. Controlled human malaria infections by intradermal injection of cryopreserved Plasmodium falciparum sporozoites. Am J Trop Med Hyg 2013, 88(1):5-13.
86. Gonzalez-Aseguinolaza G., Van Kaer L., Bergmann C.C., Wilson J.M., Schmieg J., Kronenberg M., et al. Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines. J Exp Med 2002, 195(5):617-624.
87. Lindner S.E., Swearingen K.E., Harupa A., Vaughan A.M., Sinnis P., Moritz R.L., et al. Total and putative surface proteomics of malaria parasite salivary gland sporozoites. Mol Cell Proteomics: MCP 2013, 12(5):1127-1143.
88. Mishra S., Rai U., Shiratsuchi T., Li X., Vanloubbeeck Y., Cohen J., et al. Identification of non-CSP antigens bearing CD8 epitopes in mice immunized with irradiated sporozoites. Vaccine 2011, 29(43):7335-7342.
89. Trieu A., Kayala M.A., Burk C., Molina D.M., Freilich D.A., Richie T.L., et al. Sterile protective immunity to malaria is associated with a panel of novel Plasmodium falciparum antigens. Mol Cell Proteomics 2011, 10(9). M111 007948, Epub 2011 May 31. 10.1074/mcp. M111.007948.
90. Moorthy V.S., Newman R.D., Okwo-Bele J-M. Malaria vaccine technology roadmap. Lancet 2013, 382(9906):1700-1701.